Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

被引：10
|
作者：
Komrokji, Rami S. [1 ]
Singh, Avani M. [2 ,3 ]
Al Ali, Najla [1 ]
Chan, Onyee [1 ]
Padron, Eric [1 ]
Sweet, Kendra [1 ]
Kuykendall, Andrew [1 ]
Lancet, Jeffrey E. [1 ]
Sallman, David A. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Hematol Oncol, Tampa, FL 33620 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 11期
关键词：
D O I：
10.1038/s41408-022-00744-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis
    Liu, Bei
    Guo, Yuancheng
    Deng, Lijuan
    Qiao, Yanhong
    Jian, Jinli
    HEMATOLOGY, 2020, 25 (01) : 414 - 423
  • [32] Role Of Hypomethylating Agents For Patients With Lower-Risk Myelodysplastic Syndrome Defined By IPSS and IPSS-R
    Moon, Joon Ho
    Sohn, Sang Kyun
    Ahn, Jae Sook
    Kim, Yeo-Kyeoung
    Kim, Hyeoung Joon
    Song, Moo-Kon
    Shin, Ho-Jin
    Chung, Joo-Seop
    Song, Ik Chan
    Jo, Deog-Yeon
    Lim, Sung Nam
    Lee, Ho Sup
    Kim, Yang Soo
    Bae, Sung Hwa
    BLOOD, 2013, 122 (21)
  • [33] Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts
    Gangat, Naseema
    McCullough, Kristen
    Johnson, Isla
    Al-Kali, Aref
    Begna, Kebede H.
    Patnaik, Mrinal M.
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Alkhateeb, Hassan
    Mangaonkar, Abhishek
    Foran, James M.
    Badar, Talha
    Palmer, Jeanne M.
    Sproat, Lisa
    Arana Yi, Cecilia Y.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E214 - E216
  • [34] What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
    Komrokji, Rami
    Al Ali, Najla
    Padron, Eric
    Lancet, Jeffrey
    Nazha, Aziz
    Steensma, David
    DeZern, Amy
    Roboz, Gail
    Garcia-Manero, Guillermo
    Sekeres, Mikkael A.
    Sallman, David
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2762 - 2767
  • [35] Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia
    Kennedy, Vanessa E.
    Hui, Gavin
    Gaut, Daria
    Mittal, Varun
    Oliai, Caspian
    Muffly, Lori S.
    Logan, Aaron C.
    Mannis, Gabriel N.
    BLOOD, 2020, 136
  • [36] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Mei, Matthew
    Salhotra, Amandeep
    Khaled, Samer
    Nakamura, Ryotaro
    Snyder, David
    O'Donnell, Margaret
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
  • [37] Molecular stratification of response and survival of venetoclax in combination with hypomethylating agents in AML.
    Maher, Keri Renee
    Bouligny, Ian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Life after hypomethylating agents in myelodysplastic syndrome: new strategies
    Santini, Valeria
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (02) : 155 - 162
  • [39] Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
    Khanam, Razwana
    Shahzad, Moazzam
    Chaudhary, Sibgha Gull
    Ali, Fatima
    Shah, Zunairah
    Pachika, Pranali S.
    Ahmed, Zahoor
    Chattaraj, Asmi
    Masood, Adeel
    Ahmed, Nausheen
    Bansal, Rajat
    Balusu, Ramesh
    Shune, Leyla
    Anwar, Faiz
    Hematti, Peiman
    McGuirk, Joseph P.
    Yacoub, Abdulraheem
    Mushtaq, Muhammad Umair
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2671 - 2678
  • [40] Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (01)
12345